bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: O S A J J M A M F J
2013: D N O

 
  Other news for:
Breast Neoplasms
Neoplasms
Genetics
 Resources from HONselect
Expanded DNA Testing Might Allow Personalized Breast Cancer Treatment
Researchers were able to pinpoint specific therapies for some women in study

By Kathleen Doheny
HealthDay Reporter

THURSDAY, Feb. 6, 2014 (HealthDay News) -- Testing the entire genetic makeup -- or all the DNA -- of tumor cells from women with advanced breast cancer may help identify patients who could be helped by specific treatments, according to new research.

The approach is considered the wave of the future by both the French researchers who conducted the study and U.S. experts.

"It is possible to deliver personalized medicine," said study researcher Dr. Fabrice Andre, of the Gustave Roussy Institute in Villejuif, France. "Until now, we could [test] one gene in a large number of patients, or larger numbers of genes in a few patients."

In the new study, the researchers evaluated the whole genome -- the entire collection of a person's genes -- of more than 400 patients. The approach is much more extensive than testing for mutations in specific genes, such as the BRCA1 and BRCA2 genetic mutations known to raise the risk of breast cancer.

From 2011 to 2012, Andre's team evaluated the women from 18 centers in France, all of whom had breast cancer that had spread. First they took biopsy samples. Then they conducted the whole-genome analysis to see if they could find unique characteristics and abnormal genes that could then be targeted for treatment in clinical trials.

Nearly half of the patients were found to have a genetic alteration that could be addressed with targeted treatment. Another 39 percent of women had rare alterations, many of which don't have treatments currently available, the researchers said.

Next, the researchers matched 55 of the women with new treatments being tested in clinical trials, targeting them to the women's specific genetic alteration. Of those, 43 women received the targeted treatments. And of those, four women had a response and nine others had stable disease for more than 16 weeks, the researchers said.

The study findings were published online Feb. 7 in the journal The Lancet Oncology.

Some of the larger cancer centers in the United States are also working on the whole-genome approach, said Dr. George Somlo, a professor of medical oncology and therapeutics research at the City of Hope Comprehensive Cancer Center, in Duarte, Calif. He reviewed the findings but was not involved in the study.

"It is very expensive, very labor intensive," he said. "In the United States, the approach is evolving."

The cost of whole-genome testing varies greatly, but some laboratories offer it for less than $10,000. Experts say the cost will drop more in the future.

Dr. Claudine Isaacs, a professor of oncology at the Georgetown Lombardi Comprehensive Cancer Center, in Washington, D.C., said the approach has advantages.

"The advantage of screening the tumor either for a large battery of mutations or doing whole-genome analysis is that it gives a much broader analysis and understanding of possible patient- or tumor-specific molecular 'drivers' for that particular tumor," said Isaacs, who also reviewed the findings. "It will pick up both suspected and unsuspected [genetic] alterations."

"I do think this is the wave of the future," she said. "The hope of such an approach is to better provide our patients with a personalized approach to their care."

As promising as the approach is, Somlo said, it's important to realize that "not every tumor needs to have whole-genome testing." It's already known that some specific mutations or changes in genetic activity will result in particular breast cancer patients benefiting from targeted therapy, he said.

For instance, he said, the drug trastuzumab (Herceptin) is used as a targeted therapy for women found to be over-activating the protein known as HER2 (human epidermal growth factor receptor).

For breast cancer patients, the difficulty of finding an effective treatment increases when the disease spreads, Somlo said.

"There are multiple mutations and the curability of those patients is very low," he said. Obtaining the genetic information in these cases would best be done as soon as possible after the cancer's spread is detected, he said.

More information

To learn more about human genomes, visit the U.S. National Institutes of Health.

SOURCE: Fabrice Andre, M.D., Ph.D., researcher, Gustave Roussy Institute, Villejuif, France; Claudine Isaacs, M.D., professor of oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.; George Somlo, M.D., professor of medical oncology and therapeutics research, City of Hope Comprehensive Cancer Center, Duarte, Calif.; Feb. 7, 2014, The Lancet Oncology, online

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=684610

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Therapeutics
Breast
Breast Neoplasms
Women
Research Personnel
DNA
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact